Zhi-Hui Zhang1,2, Xin-Yue Lian1,2, Dong-Ming Yao3,2, Pin-Fang He3,2, Ji-Chun Ma3,2, Zi-Jun Xu3,2, Hong Guo3,2, Wei Zhang1,2, Jiang Lin4,5, Jun Qian6,7. 1. Department of Hematology, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. 2. The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China. 3. Laboratory Center, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. 4. Laboratory Center, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. linjiangmail@sina.com. 5. The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China. linjiangmail@sina.com. 6. Department of Hematology, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. qianjun0007@hotmail.com. 7. The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China. qianjun0007@hotmail.com.
Abstract
PURPOSE: A systematic review and meta-analysis were performed to explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation with a reduced intensity conditioning regimen in elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). METHODS: Overall survival (OS) and event-free survival (EFS) were established as the primary endpoints for directly assessing the efficacy, and non-relapse mortality (NRM) for safety. The eligible patients were at or above 50 years of age, and the outcomes of the typical elderly patients (≥60 years) were analyzed individually. RESULTS: The pooled estimates (95% confidence interval (CI)) for 1-year OS, EFS and NRM were 65 (55-74) %, 50 (44-55) % and 26 (21-30) %, respectively; as for the patients ≥60 years of age, these were 63 (53-72) %, 46 (41-50) % and 28 (23-32) %, respectively. No significantly statistical difference achieved between MDS and AML patients in 1-year EFS and NRM [relative risk (RR) 0.91, 95% CI 0.80-1.04; P = 0.172 and RR 1.18, 95% CI 0.82-1.69; P = 0.365]. The patients with lower diseases risk had the possibility of higher OS rate at ≥ 3 years than those with higher diseases risk (RR 1.37, 95% CI 0.95-1.97; P = 0.088). The patients had significantly higher 2-year OS and EFS rates in complete remission (CR, CR1 and CR2) at transplantation compared to those with advanced diseases (P < 0.05). CONCLUSIONS: RIC-alloHSCT is a feasible treatment option for the patients older than 50 year of age with MDS and AML. Advanced diseases status and higher diseases risk may be the poor factors for prognosis.
PURPOSE: A systematic review and meta-analysis were performed to explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation with a reduced intensity conditioning regimen in elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). METHODS: Overall survival (OS) and event-free survival (EFS) were established as the primary endpoints for directly assessing the efficacy, and non-relapse mortality (NRM) for safety. The eligible patients were at or above 50 years of age, and the outcomes of the typical elderly patients (≥60 years) were analyzed individually. RESULTS: The pooled estimates (95% confidence interval (CI)) for 1-year OS, EFS and NRM were 65 (55-74) %, 50 (44-55) % and 26 (21-30) %, respectively; as for the patients ≥60 years of age, these were 63 (53-72) %, 46 (41-50) % and 28 (23-32) %, respectively. No significantly statistical difference achieved between MDS and AMLpatients in 1-year EFS and NRM [relative risk (RR) 0.91, 95% CI 0.80-1.04; P = 0.172 and RR 1.18, 95% CI 0.82-1.69; P = 0.365]. The patients with lower diseases risk had the possibility of higher OS rate at ≥ 3 years than those with higher diseases risk (RR 1.37, 95% CI 0.95-1.97; P = 0.088). The patients had significantly higher 2-year OS and EFS rates in complete remission (CR, CR1 and CR2) at transplantation compared to those with advanced diseases (P < 0.05). CONCLUSIONS: RIC-alloHSCT is a feasible treatment option for the patients older than 50 year of age with MDS and AML. Advanced diseases status and higher diseases risk may be the poor factors for prognosis.
Authors: A G Dinmohamed; O Visser; Y van Norden; N M A Blijlevens; J J Cornelissen; G A Huls; P C Huijgens; P Sonneveld; A A van de Loosdrecht; G J Ossenkoppele; B Löwenberg; M Jongen-Lavrencic Journal: Leukemia Date: 2015-07-17 Impact factor: 11.528
Authors: Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2011-06-21 Impact factor: 5.742
Authors: R F Schlenk; F Hartmann; M Hensel; W Jung; R Weber-Nordt; A Gabler; R Haas; A D Ho; L Trümper; H Döhner Journal: Leukemia Date: 2002-04 Impact factor: 11.528
Authors: Raymond Wong; Sergio A Giralt; Thomas Martin; Daniel R Couriel; Athanasios Anagnostopoulos; Chitra Hosing; Borje S Andersson; Pedro Cano; Munir Shahjahan; Cindy Ippoliti; Elihu H Estey; John McMannis; James L Gajewski; Richard E Champlin; Marcos de Lima Journal: Blood Date: 2003-07-03 Impact factor: 22.113
Authors: Rodrigo Martino; María Dolores Caballero; José Antonio Pérez-Simón; José Antonio Pérez Simón; Carmen Canals; Carlos Solano; Alvaro Urbano-Ispízua; Joan Bargay; Angel Léon; Josep Sarrá; Guillermo F Sanz; José María Moraleda; Salut Brunet; Jesús San Miguel; Jorge Sierra Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Steven M Devine; Kouros Owzar; William Blum; Flora Mulkey; Richard M Stone; Jack W Hsu; Richard E Champlin; Yi-Bin Chen; Ravi Vij; James Slack; Robert J Soiffer; Richard A Larson; Thomas C Shea; Vera Hars; Alexander B Sibley; Sergio Giralt; Shelly Carter; Mary M Horowitz; Charles Linker; Edwin P Alyea Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544